REDWOOD CITY, Calif., June 20, 2016 (GLOBE NEWSWIRE) -- Biotricity, Inc. (OTCQB:BTCY), a medical
diagnostic and consumer healthcare technology company dedicated to delivering innovative, biometric remote monitoring solutions,
has filed for a 510(k) with the U.S. Food and Drug Administration (FDA). Biotricity expects to receive a response from the FDA on
its 510(k) submission by early Fall.
Upon final release Biotricity’s flagship product, the bioflux solution, will combine a proprietary mobile ECG monitoring device
and an industry leading ECG viewer software package. The combination will enable physicians to remotely monitor and diagnose
patients with cardiovascular disease and coronary heart disease by detecting arrhythmias, using an accredited 24 hour, 7 day per
week, ECG monitoring facility.
Biotricity founder and CEO Waqaas Al-Siddiq commented, "Submitting for a 510(k) is a very important milestone for the company as
we prepare to commercialize our first medical solution. We believe significant opportunity exists for our remote patient monitoring
solutions to gain traction in the rapidly expanding diagnostic and preventative healthcare markets.”
About Biotricity Inc.
Biotricity is a modern medical technology company focused on delivering innovative, remote biometric monitoring solutions to the
medical and consumer markets, including diagnostic and post-diagnostic solutions for chronic conditions and lifestyle improvement.
Biotricity’s R&D continues to focus on the preventative healthcare market, with a vision of putting health management into the
hands of the individual. The company aims to support the self-management of critical and chronic conditions with the use of
innovative solutions to ease the growing burden on the healthcare system. To learn more, visit www.biotricity.com.
Important Cautions Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements.
Forward-looking statements may include, without limitation, statements regarding (i) the plans and objectives of management for
future operations, including plans or objectives relating to the design, development and commercialization of
bioflux or any of the Company’s other proposed products or services, (ii) a projection of income (including
income/loss), earnings (including earnings/loss) per share, capital expenditures, dividends, capital structure or other financial
items, (iii) the Company's future financial performance and (iv) the assumptions underlying or relating to any statement described
in points (i), (ii) or (iii) above. Such forward-looking statements are not meant to predict or guarantee actual results,
performance, events or circumstances and may not be realized because they are based upon the Company's current projections, plans,
objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other
influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may
differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that
may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from
expected or desired results may include, without limitation, the Company's inability to obtain additional financing, the
significant length of time and resources associated with the development of its products and related insufficient cash flows and
resulting illiquidity, the Company's inability to expand the Company's business, significant government regulation of medical
devices and the healthcare industry, lack of product diversification, existing or increased competition, results of arbitration and
litigation, stock volatility and illiquidity, and the Company's failure to implement the Company's business plans or strategies.
These and other factors are identified and described in more detail in the Company's filings with the SEC. The Company assumes no
obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of
this release.
Media Contacts McCoin & Smith Communications Inc. Chris McCoin, Chris@mccoinsmith.com, 508-429-5988 Richard Smith, rick@mccoinsmith.com, 978-433-3304 Investor Relations: Michael Koehler Liolios Group, Inc. BTCY@liolios.com, 949-574-3860
